PDF(Pubmed)
Abstract：
UNASSIGNED: Although the Americas and Europe have historically dominated the global research landscape, emerging economies - Brazil, Russia, India, China, and South Africa (BRICS) have significantly increased their contributions in recent years. This article studies clinical trial trends in the BRICS nations between 2018 and 2022 and compares it with trends in the G7 nations (comprising Canada, France, Germany, Italy, Japan, the UK, the USA, and the European Union). This will help stakeholders in planning drug development strategies.
UNASSIGNED: Data were collected from the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) and the World Bank database. An electronic search was done for the total number of trials registered between January 1, 2018, and March 15, 2023. Information was analyzed based on the year of registration, therapeutic area, type of intervention, sponsorship, and type of special population. The trial density indices (TDIs) were calculated based on population (Xi) and gross domestic product (GDP) (Yi) using author-derived formulae.
UNASSIGNED: Altogether 2, 77, 536 trials from the BRICS and G7 were registered. China and the US had the most trials among the BRICS and G7, respectively. Between 2018 and 2022, the gap between the BRICS and G7 steadily reduced. The most common indication for clinical trials among the BRICS was cancer. Based on population, the TDI was the highest in China and the lowest in Russia. In proportion to the GDP, the TDI was maximum in Russia and minimum in India.
UNASSIGNED: There is a remarkable reduction in the gap in clinical trial trends between the BRICS and G7 nations. Among the BRICS, India and China are at the forefront in drug development. There is scope for improvement in trial density based on India\'s population and GDP. Stakeholders are likely to utilize the strengths of the BRICS as an attractive destination for investment in this area.
UNASSIGNED: Data were collected from the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) and the World Bank database. An electronic search was done for the total number of trials registered between January 1, 2018, and March 15, 2023. Information was analyzed based on the year of registration, therapeutic area, type of intervention, sponsorship, and type of special population. The trial density indices (TDIs) were calculated based on population (Xi) and gross domestic product (GDP) (Yi) using author-derived formulae.
UNASSIGNED: Altogether 2, 77, 536 trials from the BRICS and G7 were registered. China and the US had the most trials among the BRICS and G7, respectively. Between 2018 and 2022, the gap between the BRICS and G7 steadily reduced. The most common indication for clinical trials among the BRICS was cancer. Based on population, the TDI was the highest in China and the lowest in Russia. In proportion to the GDP, the TDI was maximum in Russia and minimum in India.
UNASSIGNED: There is a remarkable reduction in the gap in clinical trial trends between the BRICS and G7 nations. Among the BRICS, India and China are at the forefront in drug development. There is scope for improvement in trial density based on India\'s population and GDP. Stakeholders are likely to utilize the strengths of the BRICS as an attractive destination for investment in this area.
摘要：
尽管美洲和欧洲在历史上一直主导着全球研究格局，新兴经济体-巴西，俄罗斯,印度,中国,近年来，南非（金砖国家）的捐款显着增加。本文研究了金砖国家在2018年至2022年之间的临床试验趋势，并将其与G7国家（包括加拿大，法国,德国,意大利,Japan,英国,美国,和欧盟)。这将有助于利益攸关方规划药物开发战略。
■数据收集自世界卫生组织国际临床试验注册平台（WHOICTRP）和世界银行数据库。对2018年1月1日至2023年3月15日之间注册的试验总数进行了电子搜索。根据注册年份对信息进行了分析，治疗区,干预类型,赞助,和特殊人群的类型。试验密度指数（TDI）是根据人口（Xi）和国内生产总值（GDP）（Yi）使用作者得出的公式计算的。
■共注册了来自金砖国家和七国集团的2、77、536项试验。中国和美国在金砖国家和七国集团中的试验最多。从2018年到2022年，金砖国家和七国集团之间的差距稳步缩小。金砖国家最常见的临床试验适应症是癌症。根据人口,TDI在中国最高，在俄罗斯最低。与GDP成比例，TDI在俄罗斯最高，在印度最低。
■金砖国家和七国集团在临床试验趋势上的差距显著缩小。在金砖国家中,印度和中国在药物开发方面处于前沿。根据印度的人口和GDP，试验密度还有改进的余地。利益相关者可能会利用金砖国家的优势作为该领域投资的有吸引力的目的地。
■数据收集自世界卫生组织国际临床试验注册平台（WHOICTRP）和世界银行数据库。对2018年1月1日至2023年3月15日之间注册的试验总数进行了电子搜索。根据注册年份对信息进行了分析，治疗区,干预类型,赞助,和特殊人群的类型。试验密度指数（TDI）是根据人口（Xi）和国内生产总值（GDP）（Yi）使用作者得出的公式计算的。
■共注册了来自金砖国家和七国集团的2、77、536项试验。中国和美国在金砖国家和七国集团中的试验最多。从2018年到2022年，金砖国家和七国集团之间的差距稳步缩小。金砖国家最常见的临床试验适应症是癌症。根据人口,TDI在中国最高，在俄罗斯最低。与GDP成比例，TDI在俄罗斯最高，在印度最低。
■金砖国家和七国集团在临床试验趋势上的差距显著缩小。在金砖国家中,印度和中国在药物开发方面处于前沿。根据印度的人口和GDP，试验密度还有改进的余地。利益相关者可能会利用金砖国家的优势作为该领域投资的有吸引力的目的地。
